Wave Life Sciences Ltd. WVE 深 沪
等待开盘 02-07 09:30:00 美东时间
13.475
+0.725
+5.69%
华盛通- 最 高19.50
- 今 开13.13
- 成交量 193.85万股
- 最 低 12.55
- 昨 收 12.75
- 总市值 116.85万
- 52周最高 21.73
- 市盈率 静 --
- 换手率 2235.49%
- 52周最低 5.28
- 委 比 -5.42%
- 总股本 8.67万
- 历史最高 56.00
- 量 比 0.74
- 振 幅 54.51%
- 历史最低 1.10
- 每 手 1
- 风险率 3.16%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Wave Life Sciences Regained Full Rights to WVE-006 From GSK
This follows agreement with GSK, whose respiratory portfolio is focused on large-scale diseases, that Wave is well placed to efficiently advance the WVE-006 program in AATD, a rare condition. This agreement was made
02-02 20:33
Wave Life Sciences One-Shot Obesity Drug Slashes Dangerous Visceral Fat
Interim data from Wave Life Sciences' INLIGHT trial showed promising results for WVE-007, an investigational treatment for obesity.
2025-12-09 02:27
Crude Oil Falls Over 1%; Structure Therapeutics Shares Jump
U.S. stocks traded lower midway through trading, with the Dow Jones index falli...
2025-12-09 01:46
US Stocks Mixed; Dow Falls Over 100 Points
U.S. stocks traded mixed this morning, with the Dow Jones index falling around ...
2025-12-08 23:04
Earnings Scheduled For November 10, 2025
Companies Reporting Before The Bell • CBAK Energy Tech (NASDAQ:CBAT) is likely ...
2025-11-10 19:12
470亿港元！“AI+机器人”新药研发订单创纪录
“AI+机器人”新药研发领域的大单来了。 8月5日晚间，港股晶泰控股宣布，公司与DoveTree Medicines LLC及其联属公司（简称“DoveT...
2025-08-06 18:16
【爱建医药】回调不改创新药产业趋势，聚焦核心赛道和产业催化
（转自：爱建证券研究所） 投资要点： 医药板块跑输沪深300，创新药大幅回调。本周（6/16~6/22）市场整体震荡向下，沪深300指数-0.45%，银行...
2025-06-25 09:15
晶泰科技与哈佛大学教授 Gregory Verdine 旗下新药公司DoveTree签署数十亿美元管线授权意向
近日，全球领先的 AI+机器人新药与新材料研发平台晶泰科技宣布，与美国哈佛大学终身教授、美国医药界的传奇创业者及投资人Gregory Verdine所设立的...
2025-06-24 11:10
Wave Life Sciences Announces Oral Presentation of Preclinical Data Supporting WVE-007’s Mechanism (INHBE) to Reduce Fat, Preserve Muscle, and Induce Healthy Weight Loss at ADA's Annual Scientific Sessions
WVE-007, a GalNAc-siRNA targeting INHBE, shows potential as a novel obesity treatment, promoting healthy weight loss by reducing Activin E and fat mass while preserving muscle. Preclinical data in DIO mice demonstrate reduced adipose inflammation and improved cardiometabolic profiles, supporting its potential to address obesity-related diseases like T2D and CAD. Clinical trials are ongoing.
2025-06-20 20:01
Wave Life Sciences to Present at 2025 Jefferies Global Healthcare Conference
Wave Life Sciences' CEO, Paul Bolno, MD, MBA, will participate in an analyst-led fireside chat at the 2025 Jefferies Global Healthcare Conference on June 4, 2025, in New York City. The company focuses on RNA medicines to address various diseases, with its PRISM® platform combining multiple modalities for therapeutic innovation.
2025-05-29 12:30
